VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
about
Tumor refractoriness to anti-VEGF therapyThe functional role of microRNA in acute lymphoblastic leukemia: relevance for diagnosis, differential diagnosis, prognosis, and therapyMechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiformeNF-κB and STAT3 in glioblastoma: therapeutic targets coming of ageIntertwined regulation of angiogenesis and immunity by myeloid cellsAnti-angiogenesis and metastasis: a tumour and stromal cell allianceBroad targeting of angiogenesis for cancer prevention and therapyTargeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signalingMechanisms of evasive resistance to anti-VEGF therapy in glioblastomaPlasticity of blood- and lymphatic endothelial cells and marker identificationDynamic quantitative intravital imaging of glioblastoma progression reveals a lack of correlation between tumor growth and blood vessel densityAdaptation to antiangiogenic therapy in neurological tumorsEffects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2Semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microgliaFighting the force: Potential of homeobox genes for tumor microenvironment regulationPhase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastomaNormalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Glioblastoma cell-secreted interleukin-8 induces brain endothelial cell permeability via CXCR2Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.Novel target for peptide-based imaging and treatment of brain tumorsVEGF targets the tumour cell.Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patientsMRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach.A new mosaic pattern in glioma vascularization: exogenous endothelial progenitor cells integrating into the vessels containing tumor-derived endothelial cells.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Contribution of the Microenvironmental Niche to Glioblastoma Heterogeneity.Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression.Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.Integrin inhibitor suppresses bevacizumab-induced glioma invasion.The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer.High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients.The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients.Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).Antiangiogenic therapy for glioblastoma: current status and future prospects.Microenvironmental induced essentiality of autophagyTargeting Src family kinases inhibits bevacizumab-induced glioma cell invasionEffects of anti-angiogenesis on glioblastoma growth and migration: model to clinical predictions.Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells.
P2860
Q26747678-1C6613D2-890D-4C4F-A8C0-FD1A7B737157Q26778301-149BCC04-06F8-4059-B006-9005CCEA9A54Q26824557-142AC4D5-CCC3-4625-BD48-F39B65CDAEEAQ26830388-ED0EEDC8-623C-4574-BDD6-C2F78202BB51Q26830418-C878EA46-6BE0-488C-B6F7-A90C2E242EDFQ26862741-B7D65F75-C308-45D7-B142-47C99E4BB613Q27002903-7D356575-57EB-46A7-B55F-324390F6F8EEQ27011423-7E06FD7D-0DC0-4899-8F3F-0EF14C647F42Q27021470-932B9416-7904-4652-B4B6-A9E92407E9A8Q27306942-BC5C6259-23C2-476A-A36D-14990EF6B016Q27308856-52AAB1DE-0DFC-4166-9F9D-284B6F5F8681Q28082908-A92AC6E8-A6AE-4340-909F-8548D160ABD0Q28487568-AACB2E16-1EE6-4A9F-9EF2-467D76090CDBQ28538650-44F32A66-E3A1-46BB-BD96-365F4180A19FQ28547302-5141564F-F98B-4541-9450-9A3AE889465BQ30278053-65F7DA9B-E487-4263-8A38-BA1A1B24A561Q30541574-DB3626F6-5BF6-4235-84D6-BAB7A6840FE6Q30542073-1D876333-199B-400B-AF9B-60484E67B424Q31101680-35931D7C-227C-4FD1-941D-036BA200BF01Q33414998-B67531B5-A22A-4406-ACE8-479F0E539D18Q33554409-6E63FD27-3AE5-431A-8FC5-DE7743F31FDAQ33573324-7609B6B8-8ECF-44F9-AA55-D10D1AEF1094Q33576750-6D312D05-B847-45AC-B740-ECC1383D2975Q33616649-C900BC63-31EE-4308-990F-C621CF57E1D6Q33639714-751D8070-2BE4-4D1B-942B-1F0D3B6C7B56Q33688374-431CF885-01D2-4E22-A079-FF699D9E1AAAQ33770680-87FAE6A0-F13E-49E3-99CC-8BF893463B47Q33786677-1D1701C8-A839-44C3-9AA6-FD29818E2A59Q33808359-C03FD184-C366-46A0-87EE-F72349368CC8Q33853991-C2327DCC-A5CA-4EF4-BE64-1CAF9E67B5CFQ33912329-4098FBD4-CD2A-4629-8A2A-DE54DDD76B17Q34134697-57F82699-CEE6-4056-B0CB-D671D234648FQ34221586-262B43CD-18AC-49D3-BEC5-EEDC41E491F3Q34293163-47C8C7B9-AFFC-465C-92A9-22F87172C723Q34478948-C28A5461-D6EC-4F21-AC8F-BFE8FD370557Q34523319-A73A8876-8FC0-47CE-A6F7-40CD425D07C7Q34589869-D4B616F9-4BCC-4125-A2BA-438C973905F4Q34606869-224D5691-CEC8-47B5-9736-0A3E70BCC808Q34703888-9CD927DB-D3B6-4254-9A75-EE7EB3731E82Q34708917-E189AB5A-1880-4EA7-B5DE-4DA9DB32895B
P2860
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
description
2012 nî lūn-bûn
@nan
2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
@ast
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
@en
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
@nl
type
label
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
@ast
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
@en
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
@nl
prefLabel
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
@ast
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
@en
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
@nl
P2093
P2860
P921
P3181
P1433
P1476
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex
@en
P2093
Christine A Parachoniak
David A Cheresh
David Meyronet
Gabriele Bergers
Jeffrey P Chang
Joanna J Phillips
Manish K Aghi
Melissa M Pandika
Morag Park
P2860
P3181
P356
10.1016/J.CCR.2012.05.037
P407
P577
2012-07-10T00:00:00Z